Product review · Updated September 30, 2026
NEOVA Power Defense care review: who can clarify a mismatched record?
The highlights and full declaration name different caprooyl peptides; that unresolved discrepancy belongs to the product-record question.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
NEOVA Power Defense offers an unusually concrete reason to separate product clarification from personal assessment. The manufacturer’s highlights name Caprooyl Tripeptide-3, while its full ingredient declaration names Caprooyl Tetrapeptide-3. The difference is visible in the retained page. We cannot resolve it through preference, familiarity with peptide names or assumptions about which part of the page is newer.
Our September 30, 2026 record review includes the official product text and selected FDA labeling and AAD assessment context. We did not contact the company, inspect a package or examine a reader’s concern. The review preserves the contradiction, the named copper ingredient and the advertised customer-service scope without claiming a correction, a professional handoff or an individual care decision.
In this article
Power Defense is a named serum, not a completed assessment
The manufacturer identifies Power Defense as an antioxidant serum with its Copper Peptide Complex and describes a lightweight gel addressing aging-related appearance concerns. Those details come from the product identity and purpose text. They describe what NEOVA advertises, rather than a measured improvement observed here or a finding about a reader’s skin.
Our consultation product-list guide provides an original companion for framing a named product question. In this case, the identity is reasonably clear even while one ingredient-name detail is not. A recognized serum name cannot substitute for resolving that detail, and neither the name nor its purpose establishes why a person has noticed a change.
The two caprooyl names must remain unresolved
The highlights say Caprooyl Tripeptide-3. The complete declaration says Caprooyl Tetrapeptide-3. We retain both spellings from the manufacturer highlights and ingredient list instead of silently selecting one or turning the mismatch into evidence of a formula change. The captured record does not explain which wording applies to a reader’s actual item.
This is a product-record clarification question. It does not establish an adulteration finding, a labeling violation or a cause of discomfort. Our Naturium care review offers another editorial reading route concerning published records. It cannot resolve NEOVA’s discrepancy, and no answer has been imported from another brand’s caveat or policy.
The copper declaration is clear within that limited record
The complete list explicitly names Bis (Tripeptide-1) Copper Acetate. That declaration supports the directory’s named-copper classification independently of the unresolved caprooyl wording. The presence of a copper name does not establish its measured concentration, the finished product’s performance or the component responsible for a reported observation.
FDA’s cosmetic labeling guide explains ingredient-order exceptions, including certain ingredients at one percent or less. We use that context to avoid quantitative inference from a list position. We have not assayed Power Defense or audited compliance. Resolving one naming discrepancy and measuring the formula would be different investigations; neither has been completed in this review.
The packaging caveat cannot choose between the names
NEOVA says formulas may be refined and website lists may differ from packaging, with packaging identified for current ingredient information. The manufacturer caveat recognizes a possible difference between records. It does not specifically explain the Tripeptide-3 versus Tetrapeptide-3 contradiction within the captured page, or establish a chronology for a reader’s container.
Our existing-actives conversation guide supplies broader context when a product question intersects with existing care. We did not read a physical label, obtain a corrected declaration or verify a refinement date. The product-version uncertainty should remain visible, rather than being converted into an instruction to change care or a claim that one edition has been clinically reviewed.
Advertised service hours describe availability, not medical response
The retained page says customer service is available Monday through Friday, 9 a.m. to 5 p.m. Eastern Time. That is the scope of the support statement we can document. It does not promise a clinician’s assessment, establish a response time or confirm that a question about this ingredient discrepancy has been answered.
We did not contact the team or observe a correction. A manufacturer may clarify its own published record, but that possibility remains different from an actual completed clarification. Our Drunk Elephant care review is an additional reading option within the collection. Neither that review nor this support-hours record supplies a professional answer to a personal skin concern.
An outcome summary cannot explain an individual concern
The manufacturer reports a 71 percent decrease in wrinkle count and a 74 percent improvement in texture in its study summary. We read the summary text, not an underlying complete report or personal result. It remains attributed marketing evidence rather than a finding that the serum produced those outcomes in this review.
AAD’s assessment guidance describes examination and relevant history when contact dermatitis is suspected. That provides a separate professional boundary: product clarification and a personal assessment have different purposes. We have no clinical evaluation, verified cause or documented care handoff. The page’s efficacy summary cannot resolve a concern, and the caprooyl mismatch cannot by itself explain one.
The useful next question retains the contradiction
The supported record includes a named serum, an explicit copper entry, an unresolved caprooyl-name discrepancy, a packaging caveat and customer-service hours. The official page establishes those facts without settling which declaration describes a specific container or what caused an individual observation. Its broader regimen language remains manufacturer context, with directions excluded from this review.
The original simple-routine comparison offers further navigation. Our conclusion is a responsibility distinction: clarification of the brand’s record and assessment of a person’s concern are separate questions. Neither has been completed here. Preserving the mismatch is more accurate than supplying a neat ingredient answer that the retained evidence does not support.
Sources behind this reading
- Power Defense | NEOVA ↗Official manufacturer product record · Checked September 30, 2026
- FDA Cosmetic Labeling Guide ↗Regulator primary: selected label passages · Checked September 30, 2026
- Eczema types: Contact dermatitis diagnosis and treatment ↗Medical society patient guidance: selected assessment and safety context · Checked September 30, 2026